Contents
On this page
Academy · Research Data Analytics & AI · PRISMA definition
PRISMA 2020: Scope, Components and Common Misinterpretations of the Reporting Guideline
PRISMA is a reporting guideline that specifies what should be reported about a systematic review that has already been conducted. It is not a method for conducting a review, not a quality appraisal instrument and not a standard that a review can be said to have followed. The most common statement in the systematic review literature, “this review was conducted according to PRISMA guidelines”, therefore represents a category error.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) comprises a checklist and a flow diagram, published by Page and colleagues in 2021 as PRISMA 2020 and released simultaneously across five journals to maximise reach. Its purpose is narrow and should be stated precisely: to help authors report what they did with sufficient transparency for a reader to judge the conduct of the review and reproduce its steps. It does not prescribe how to search, appraise or synthesise. Confusing the reporting guideline with the method is the single most common misuse in the literature.
Learning objectives
- The components of PRISMA 2020 and the purpose of each
- The three functions PRISMA is routinely mistaken for, and the appropriate alternative for each
- Which extension applies to a given review type: scoping, diagnostic accuracy, network, individual participant data, protocol, living, harms, equity or search reporting
- The correct citation of PRISMA in a methods section
- What complete PRISMA reporting cannot tell a reader about a review
Common misconceptions
- “We conducted the review in accordance with PRISMA.” PRISMA governs reporting, not conduct. Page and colleagues state this explicitly in the statement itself: it is not intended to guide the conduct of systematic reviews.
- “PRISMA compliance means the review is of good quality.” A completely reported review may nonetheless have been poorly conducted. The checklist records what was done; it does not evaluate it.
- “PRISMA is a quality appraisal tool for included studies.” It is not an appraisal instrument at any level — neither for the review nor for the studies in it. Risk-of-bias assessment is a separate step with separate tools.
- “PRISMA 2020 is just PRISMA 2009 reformatted.” The 2020 statement revises the items, restructures the reporting of search strategies and synthesis methods, and adds a checklist for abstracts.
- “One PRISMA covers every review type.” There are extensions for scoping reviews, diagnostic accuracy, network meta-analysis, individual participant data, protocols, living reviews, harms, equity, complex interventions and search reporting.
Components of PRISMA 2020
PRISMA 2020 has three components. The first is the main checklist, organised by the sections of a review report — title, abstract, introduction, methods, results, discussion and other information such as funding, conflicts and data availability. Each item names something that must appear in the report and, in the accompanying explanation and elaboration material, states why a reader needs it. The second is a checklist for abstracts, because a large proportion of readers do not read beyond the abstract and require different information there. The third is the flow diagram, which accounts for records from identification through to inclusion.
Page and colleagues published the statement in parallel across five journals — PLoS Medicine, the BMJ, the International Journal of Surgery, the Journal of Clinical Epidemiology and Systematic Reviews — which itself indicates the intent. A reporting guideline is effective only if the authors, editors and reviewers in every relevant field have access to the same version, so it was distributed rather than placed 27.
Two features of the structure merit attention. The items are organised by where they appear in a manuscript, not by the order in which a review is conducted, which is the clearest structural evidence that it is a reporting instrument. In addition, several items ask for a decision and its justification rather than the decision alone, which is why the checklist is far more useful at protocol stage than at submission.
Three functions PRISMA does not serve
Not a method for conducting a review. PRISMA contains no guidance on how to construct a search, who should screen, how disagreements should be resolved, which risk-of-bias tool to use, or which statistical model to fit. It requires authors to report all of these. The methodological guidance is found elsewhere — principally in the Cochrane Handbook and the primary methods literature. Our meta-analysis methodology walkthrough covers the analytic decisions that PRISMA requires authors to describe.
Not a quality appraisal instrument. PRISMA does not score a review and does not generate a judgement about one. A review can satisfy every item and still have used an inadequate search, relied on a single screener and pooled studies that should not have been combined; it will simply have reported these features clearly, which is the purpose of the guideline. Appraising a review’s conduct, and appraising the risk of bias in its included studies, are two further separate exercises with their own instruments.
Not a standard a review “follows” or “complies with”. A review can be reported in accordance with PRISMA; it cannot be conducted in accordance with it, because PRISMA does not specify what to do. The distinction may appear pedantic, but in a manuscript the sentence usually substitutes for a description of the methods, as if naming the guideline discharged the obligation to state what was done.
Purpose of the flow diagram
The flow diagram is the component most authors complete and the one most often completed incorrectly. Its purpose is to allow a reader to follow every record from identification to inclusion and to see where the remaining records went, with reasons at the exclusion steps. When completed properly, it is a reproducibility artefact: a reader who re-runs the search should obtain a figure in the same region as that in the first box.
A worked example illustrates the structure. Veroniki and colleagues, reviewing methods for calculating uncertainty in random-effects meta-analysis, searched PubMed from inception to 29 April 2016, retrieved 5,628 records, added 20 further records from other sources, and finished with 69 publications meeting the eligibility criteria 37. The attrition from several thousand to several dozen is entirely typical, and it is informative: it indicates how specific the eligibility criteria were relative to the search.
Two errors are common. The first is numbers that do not reconcile down the diagram, which is the first thing a methods reviewer checks and the quickest way to lose that reviewer’s confidence. The second is exclusion counts without reasons at the full-text stage, which is where the reader most needs them, because that is where judgement was exercised. Rethlefsen and colleagues’ PRISMA-S extension in Systematic Reviews covers search reporting in the detail the main checklist leaves out, including how to report database-by-database yields that the diagram collapses 4.
A worked flow diagram, showing the typical attrition a PRISMA diagram has to account for. Figures from the PubMed search, inception to 29 April 2016, reported in Veroniki AA, Jackson D, Bender R, Kuss O, Langan D, Higgins JPT, Knapp G, Salanti G. Methods to calculate uncertainty in the estimated overall effect size from a random-effects meta-analysis.
PRISMA extensions and their applicability
The main checklist assumes a systematic review of intervention effects. Review types that differ structurally have their own extensions, each published as a checklist with explanatory material, and using the wrong one produces a report that omits the items a reader of that review type most needs.
Three merit particular attention. PRISMA-ScR, published by Tricco and colleagues in the Annals of Internal Medicine, exists because scoping reviews answer a mapping question rather than an effect question and should not be reported as though they had pooled anything 9. PRISMA-DTA, published by McInnes and colleagues in JAMA in 2018, covers diagnostic test accuracy reviews, where the unit of result is a pair of linked estimates rather than a single effect — see our pages on cardiovascular imaging AI reviews and CNN radiology reviews for what that changes in practice; Cohen and colleagues later added a version for journal and conference abstracts in the BMJ 5,10. And PRISMA-P, published by Moher and colleagues in Systematic Reviews, covers protocols — the extension that most reviewers should consult first and usually consult last 15.
Beyond these: PRISMA-NMA for network meta-analyses (Hutton and colleagues), PRISMA-IPD for individual participant data reviews (Stewart and colleagues), the PRISMA harms checklist (Zorzela and colleagues), PRISMA-Equity (Welch and colleagues), PRISMA-CI for complex interventions (Guise and colleagues), PRISMA-S for searches, PRISMA-LSR for living systematic reviews (Akl and colleagues), PRISMA-COSMIN for reviews of outcome measurement instruments (Elsman and colleagues), and field-specific extensions including PRISMA-CHM for Chinese herbal medicines and a moxibustion extension (Zhang and colleagues) 2,3,6,7,11,12,14,17,20. For qualitative synthesis, ENTREQ — published by Tong and colleagues in BMC Medical Research Methodology — is the separate guideline, not a PRISMA extension 19.
Which PRISMA extension applies to which review
| Extension | Applicable when the review is | Published in |
|---|---|---|
| PRISMA 2020 (main statement) | A systematic review, typically of intervention effects | PLoS Medicine, BMJ and three further journals in parallel |
| PRISMA-P | A protocol for a review not yet conducted | Systematic Reviews — Moher and colleagues |
| PRISMA-ScR | A scoping review mapping a literature rather than estimating an effect | Annals of Internal Medicine — Tricco and colleagues |
| PRISMA-DTA | A review of diagnostic test accuracy, pooling paired sensitivity and specificity | JAMA — McInnes and colleagues; abstracts version in the BMJ |
| PRISMA-NMA | A review comparing more than two interventions in a network | Annals of Internal Medicine — Hutton and colleagues |
| PRISMA-IPD | A review synthesising individual participant data | JAMA — Stewart and colleagues |
| PRISMA harms | A review whose outcomes include adverse effects | BMJ — Zorzela and colleagues |
| PRISMA-Equity | A review with an explicit health-equity focus | PLoS Medicine and International Journal for Equity in Health — Welch and colleagues |
| PRISMA-CI | A review of complex interventions with interacting components | Journal of Clinical Epidemiology — Guise and colleagues |
| PRISMA-S | Any review — for reporting the search itself in full | Systematic Reviews — Rethlefsen and colleagues |
| PRISMA-LSR | A living systematic review, updated on an ongoing basis | BMJ — Akl and colleagues |
| PRISMA-COSMIN | A review of outcome measurement instruments | Journal of Clinical Epidemiology — Elsman and colleagues |
Compiled from each extension’s own publication. Field-specific extensions also exist, including PRISMA-CHM for Chinese herbal medicines and an extension for moxibustion. For qualitative evidence synthesis, ENTREQ is a separate guideline rather than a PRISMA extension.
Correction of the common misuse statement
The sentence to look for in a methods section is some variant of “this systematic review was conducted in accordance with the PRISMA guidelines”. It appears in a very large share of published reviews and has three unhelpful effects. It attributes to PRISMA an authority it does not claim. It implies that a methodological standard was met when none was specified. Finally, it usually replaces the description of what was done, so that a reader seeking to understand how screening was conducted finds the guideline’s name where the method should be.
The correction is one clause longer and conveys information. The review should be reported in accordance with PRISMA 2020, stated in those terms, with the statement cited, the extension named if one applies, and the completed checklist placed in the supplement with page or section numbers. The conduct should then be described separately, citing the methodological source actually followed.
Citing PRISMA in a methods section
Treats PRISMA as method
This systematic review and meta-analysis was conducted in accordance with the PRISMA guidelines. A comprehensive literature search was performed and relevant studies were selected by the review team.
“Conducted in accordance with PRISMA” is not possible. PRISMA says what to report, not what to do; Page and colleagues state in the statement that it is not intended to guide review conduct.
No methodological source named. The guideline’s name has been put where the method should be, so the reader learns nothing about how the review was run.
No checklist location. A PRISMA claim with no completed checklist cannot be checked against anything.
“Comprehensive” and “relevant” are unverifiable. The identity and number of screeners, the criteria applied and the method of resolving disagreements are all absent.
No extension named. For a diagnostic accuracy, scoping, network or IPD review, the main checklist alone omits the items that review type most needs.
Treats PRISMA as reporting
This review is reported in accordance with the PRISMA 2020 statement; the completed checklist, with the section in which each item is addressed, is in Supplementary File 1, and the search is reported following PRISMA-S. The review was conducted following the methods set out in the Cochrane Handbook for Systematic Reviews of Interventions, and the protocol was registered prospectively and prepared using PRISMA-P. Two reviewers screened all titles and abstracts independently against the pre-specified eligibility criteria, with disagreements resolved by a third reviewer; full-text screening followed the same procedure and reasons for exclusion were recorded at that stage.
Reporting and conduct are attributed to their correct sources, so that neither claim substitutes for the other.
The checklist is located and item-mapped, which is what makes the PRISMA claim verifiable rather than decorative.
Screening is described concretely — number of reviewers, independence, arbitration, when reasons were recorded — so the flow diagram’s numbers have a procedure behind them.
PRISMA-S and PRISMA-P are named where they apply, signalling that the search and the protocol were reported to their own standards.
Everything claimed here is checkable by a reader against the supplement, which is the entire purpose of a reporting guideline.
The second version makes two separate, checkable claims where the first made one uncheckable claim. It also requires no additional effort if the checklist was maintained from protocol stage rather than reconstructed at submission.
Limitations of complete PRISMA reporting
Transparent reporting exposes problems; it does not fix them. Three bodies of work illustrate this limitation, and each is a reason to read a fully PRISMA-reported review critically rather than uncritically.
Chan and colleagues, in JAMA, compared trial protocols with their publications and documented discrepancies in reported outcomes 33. Turner and colleagues, in the New England Journal of Medicine, compared the published literature on a drug class against the regulatory record 30. Wood and colleagues, in the BMJ, examined how design features relate to estimated treatment effects 29. A review can report its own methods impeccably and still inherit all of this from its inputs: selective outcome reporting inside the included trials, a publication record that is not the evidence record, and design-related bias that no amount of reporting clarity removes.
There is a statistical version of the same point. A review can satisfy the synthesis items in full and still report a pooled estimate that is fragile to a methodological choice. Veroniki and colleagues showed how much the confidence interval around a random-effects summary depends on the method used to calculate it, and Higgins and Thompson, in Statistics in Medicine, set out why heterogeneity has to be described rather than tested through 34,37. Riley, Higgins and Deeks, in the BMJ, argue the summary mean is frequently the wrong number to report on its own 22. PRISMA requires these matters to be reported; it cannot ensure that they are favourable. Our page on what pooling buys you covers that gap.
Timing of checklist use
PRISMA is of little value as a submission formality but of considerable value as a drafting instrument, for one reason: a number of its items ask for a decision and the justification for it, and those justifications can only be written honestly before the results are known 18. An item asking why a particular synthesis model was chosen is straightforward to answer in a protocol and difficult to answer once a forest plot exists.
The practical sequence is therefore to read the relevant extension and PRISMA-P while writing the protocol, to use the item list to structure the protocol itself, and to maintain the completed checklist as a living document throughout the review. At submission, it is then a record rather than a reconstruction. Our reporting guidelines overview covers how this works across CONSORT, STROBE and the rest, and systematic review support is where the conduct decisions are made.
Key points
Key points
PRISMA 2020 is a reporting guideline comprising a main checklist, an abstract checklist and a flow diagram, published in parallel across five journals by Page and colleagues. It specifies what should be reported about a review that has already been conducted. It is not a method, not an appraisal instrument and not a standard in accordance with which a review can be conducted, as the statement itself makes clear. Authors should select the extension that matches their review type, use the item list while writing the protocol rather than at submission, and describe their conduct by citing the methodological source actually followed.
Application to your study
Application to your study
- The misuse statement should be revised. The phrase “conducted in accordance with PRISMA” should be replaced with “reported in accordance with the PRISMA 2020 statement”, and the statement should be cited.
- The methodological source should be cited separately. The methodological guidance actually followed for searching, screening, appraisal and synthesis should be stated in a separate sentence with its own citation.
- The applicable extension should be identified before drafting. For scoping, diagnostic accuracy, network, individual participant data (IPD), harms, equity, complex intervention or living reviews, the main checklist alone omits items that are required.
- PRISMA-P should be used while the protocol is being written. The items requiring a justification can be answered honestly only before results exist.
- The search should be reported in accordance with PRISMA-S. Reporting should include database-by-database strategies and yields rather than a narrative summary of the sources searched.
- The flow diagram should be reconciled arithmetically. Numbers must sum correctly at every step, and reasons must be given for full-text exclusions.
- The completed checklist should be submitted with section numbers. Each item should be mapped to its location in the manuscript, rather than marked with a tick.
- Complete reporting should not be presented as a claim of quality. The limitations of the review should be stated substantively; the checklist does not make that argument on the authors’ behalf.
Frequently asked questions
Preferred Reporting Items for Systematic Reviews and Meta-Analyses. It is a reporting guideline with three components: a main checklist organised by the sections of a review report, a separate checklist for abstracts, and a flow diagram accounting for records from identification to inclusion. The current version is PRISMA 2020, published by Page and colleagues in parallel across five journals — PLoS Medicine, the BMJ, the International Journal of Surgery, the Journal of Clinical Epidemiology and Systematic Reviews. Its purpose is to make a review’s conduct transparent enough for a reader to judge and reproduce, not to prescribe how the review should be done.
Yes, and the statement itself says so: PRISMA is not intended to guide the conduct of systematic reviews. The checklist contains no instruction on how to build a search, how many people should screen, which risk-of-bias tool to apply or which statistical model to fit; it requires authors to report all of these. Authors should write “reported in accordance with the PRISMA 2020 statement” and then name, in a separate sentence, the methodological source actually followed. This matters in practice because the incorrect phrasing usually appears in place of a methods description rather than alongside one.
No. PRISMA produces no score and no judgement, and a review can address every item while having been conducted poorly; it will simply have reported that clearly, which is the purpose of the guideline. Completeness of reporting and quality of conduct are different properties, and appraising a review’s conduct is a separate exercise using instruments designed for it. Likewise, PRISMA is not a tool for appraising the studies within a review: risk-of-bias assessment of included studies is a separate step, and PRISMA asks only that authors report which tool was used and what was found.
PRISMA 2020, published by Page and colleagues, is a substantive revision rather than a reformat. It revises the item set, asks for considerably more detail on how searches were constructed and run, restructures the reporting of synthesis methods so that model choice, heterogeneity assessment and sensitivity analyses are reported explicitly, and adds a dedicated checklist for abstracts. The flow diagram was also revised. Where a protocol or draft was prepared against the 2009 checklist, the gaps are most likely to be found in the synthesis and search items.
The extension should match the review type. PRISMA-P for protocols; PRISMA-ScR for scoping reviews, published by Tricco and colleagues in the Annals of Internal Medicine; PRISMA-DTA for diagnostic test accuracy reviews, published by McInnes and colleagues in JAMA in 2018, with a separate abstracts version by Cohen and colleagues; PRISMA-NMA for network meta-analyses; PRISMA-IPD for individual participant data; PRISMA harms; PRISMA-Equity; PRISMA-CI for complex interventions; PRISMA-S for reporting the search; PRISMA-LSR for living reviews; and PRISMA-COSMIN for reviews of outcome measurement instruments. For qualitative evidence synthesis, ENTREQ is a separate guideline, not a PRISMA extension.
Most journals require it, and reviewers check two things first. The first is whether the numbers reconcile down the diagram — records identified, duplicates removed, screened, full texts assessed, included — because arithmetic that does not reconcile is the quickest way to lose a reviewer’s confidence. The second is whether exclusions at the full-text stage carry reasons, since that is the step at which judgement was exercised and where a reader needs to see it. A published example of the attrition involved: Veroniki and colleagues retrieved 5,628 records plus 20 from other sources and ended with 69 eligible publications.
Not on that basis alone. Complete reporting exposes problems rather than removing them, and a review inherits the defects of its inputs. Chan and colleagues documented discrepancies between trial protocols and publications in JAMA; Turner and colleagues compared a published drug literature against the regulatory record in the New England Journal of Medicine; Wood and colleagues examined how design features relate to estimated effects in the BMJ. There is also a statistical dimension: Veroniki and colleagues showed how much a random-effects confidence interval depends on the calculation method chosen. PRISMA requires these matters to be reported but cannot ensure that they are favourable.
At protocol stage, which is the opposite of normal practice. Several PRISMA items ask not only what was decided but why, and those justifications can only be written honestly before the results are visible. An item asking why a particular synthesis model was chosen is straightforward to answer in a protocol and difficult to answer once a forest plot exists. The relevant extension and PRISMA-P should be read while drafting the protocol, the item list should be used to structure the protocol itself, and the completed checklist should be updated throughout the review so that at submission it is a record rather than a reconstruction.
References
- Noyes J, Booth A, Hannes K, Harden A, Harris J, Lewin S, et al. Supplemental guidance for inclusion of qualitative research in Cochrane systematic reviews of interventions. Cochrane Collaboration Qualitative Methods Group (guidance). 2016. read 9 October 2026. frontiersin.org
- Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, et al. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024. Journal of Clinical Epidemiology. 2024:111422. read 9 October 2026. resources.equator-network.org
- Akl EA, Meerpohl JJ, Elliott J, Brennan SE, Hemkens LG, Hilton J, et al. Living systematic reviews: reporting guidance (PRISMA-LSR). BMJ. 2024;387:e079183. read 9 October 2026. resources.equator-network.org
- Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews. Systematic Reviews. 2021;10(1):39. read 9 October 2026. resources.equator-network.org
- Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, et al. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. read 9 October 2026. resources.equator-network.org
- Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, et al. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). The American Journal of Chinese Medicine. 2020;48(6):1279-1313. read 9 October 2026. resources.equator-network.org
- Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang X, et al. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Systematic Reviews. 2020;9(1):247. read 9 October 2026. resources.equator-network.org
- Wang X, Chen Y, Yao L, Zhou Q, Wu Q, Estill J, et al. Reporting of declarations and conflicts of interest in WHO guidelines can be further improved (PRISMA-A). BMC Complementary and Alternative Medicine. 2019;19(1):208. read 9 October 2026. resources.equator-network.org
- Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Annals of Internal Medicine. 2018. doi:10.7326/M18-0850 read 9 October 2026. doi.org/10.7326/M18-0850
- McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, et al. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396. doi:10.1001/jama.2017.19163 read 9 October 2026. doi.org/10.1001/jama.2017.19163
- Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P. AHRQ series on complex intervention systematic reviews-paper 6: PRISMA-CI extension statement and checklist. Journal of Clinical Epidemiology. 2017. read 9 October 2026. resources.equator-network.org
- Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. read 9 October 2026. resources.equator-network.org
- Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration. International Journal for Equity in Health. 2015;14(1):92. read 9 October 2026. resources.equator-network.org
- Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF. Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data: The PRISMA-IPD Statement. JAMA. 2015;313(16):1657-1665. read 9 October 2026. resources.equator-network.org
- Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015. Systematic Reviews. 2015;4(1):1. read 9 October 2026. resources.equator-network.org
- Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG, Moher D, Rennie D, de Vet HCW, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF; STARD Group. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527. doi:10.1136/bmj.h5527 read 9 October 2026. doi.org/10.1136/bmj.h5527
- Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JPA, Straus S, Thorlund K, Jansen JP, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Annals of Internal Medicine. 2015;162(11):777-784. read 9 October 2026. resources.equator-network.org
- Hirst A, Altman DG. Are peer reviewers encouraged to use reporting guidelines? A survey of 116 health research journals. PLoS One. 2012;7:e35621. read 9 October 2026. trialsjournal.biomedcentral.com
- Tong A, Flemming K, McInnes E, Oliver S, Craig J. Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ. BMC Medical Research Methodology. 2012;12:181. doi:10.1186/1471-2288-12-181 read 9 October 2026. doi.org/10.1186/1471-2288-12-181
- Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H. PRISMA-Equity 2012 extension: reporting guidelines for systematic reviews with a focus on health equity. PLoS Medicine. 2012;9(10):e1001333. read 9 October 2026. resources.equator-network.org
- Schiller P, Burchardi N, Niestroj M, Kieser M. Quality of reporting of clinical non-inferiority and equivalence randomised trials: update and extension. Trials. 2012;13:214. doi:10.1186/1745-6215-13-214 read 9 October 2026. doi.org/10.1186/1745-6215-13-214
- Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549. doi:10.1136/bmj.d549 read 9 October 2026. doi.org/10.1136/bmj.d549
- Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, Carpenter J, Rucker G, Harbord RM, Schmid CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Schwarzer G, Duval S, Altman DG, Moher D, Higgins JPT. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002. doi:10.1136/bmj.d4002 read 9 October 2026. doi.org/10.1136/bmj.d4002
- Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010. read 9 October 2026. trialsjournal.biomedcentral.com
- Viechtbauer W. Conducting meta-analyses in R with the metafor package. Journal of Statistical Software. 2010;36(3):1-48. doi:10.18637/jss.v036.i03 read 9 October 2026. doi.org/10.18637/jss.v036.i03
- Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG. The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ. 2010;340:c723. read 9 October 2026. trialsjournal.biomedcentral.com
- Simera I, Moher D, Hirst A, Hoey J, Schulz KF, Altman DG. Transparent and accurate reporting increases reliability, utility, and impact of your research: reporting guidelines and the EQUATOR Network. BMC Medicine. 2010;8:24. read 9 October 2026. trialsjournal.biomedcentral.com
- Barnett-Page E, Thomas J. Methods for the synthesis of qualitative research: a critical review. BMC Medical Research Methodology. 2009;9(1):59. read 9 October 2026. doaj.org
- Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. BMJ. 2008;336:601-605. read 9 October 2026. lshtm-eprints-repo-prod.lshtm-eprints.cdl.cosector.com
- Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. New England Journal of Medicine. 2008;358:252-260. read 9 October 2026. lshtm-eprints-repo-prod.lshtm-eprints.cdl.cosector.com
- Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, Gaboury I. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Medical Journal of Australia. 2006;185:263-267. read 9 October 2026. trialsjournal.biomedcentral.com
- Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006;295:1152-1160. read 9 October 2026. trialsjournal.biomedcentral.com
- Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. JAMA. 2004;291:2457-2465. read 9 October 2026. lshtm-eprints-repo-prod.lshtm-eprints.cdl.cosector.com
- Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine. 2002;21(11):1539-1558. doi:10.1002/sim.1186 read 9 October 2026. doi.org/10.1002/sim.1186
- Moher D, Schulz KF, Altman DG; CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357:1191-1194. read 9 October 2026. trialsjournal.biomedcentral.com
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials. 1986;7(3):177-188. doi:10.1016/0197-2456(86)90046-2 read 9 October 2026. doi.org/10.1016/0197-2456(86)90046-2
- Veroniki AA, Jackson D, Bender R, Kuss O, Langan D, Higgins JPT, Knapp G, Salanti G. Methods to calculate uncertainty in the estimated overall effect size from a random-effects meta-analysis. doi:10.1002/jrsm.1319 read 9 October 2026. doi.org/10.1002/jrsm.1319
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 9). PRISMA 2020: Scope, Components and Common Misinterpretations of the Reporting Guideline. Pubrica. https://pubrica.com/academy/concepts-definitions/preferred-reporting-items-for-systematic-reviews-and-meta-analyses/
Pubrica Academy. “PRISMA 2020: Scope, Components and Common Misinterpretations of the Reporting Guideline.” Pubrica, 9 Oct. 2026, pubrica.com/academy/concepts-definitions/preferred-reporting-items-for-systematic-reviews-and-meta-analyses/.
Pubrica Academy (2026) PRISMA 2020: Scope, Components and Common Misinterpretations of the Reporting Guideline. Pubrica. Available at: https://pubrica.com/academy/concepts-definitions/preferred-reporting-items-for-systematic-reviews-and-meta-analyses/ (Accessed: 15 October 2026).
Pubrica Academy. “PRISMA 2020: Scope, Components and Common Misinterpretations of the Reporting Guideline.” Pubrica. October 9, 2026. https://pubrica.com/academy/concepts-definitions/preferred-reporting-items-for-systematic-reviews-and-meta-analyses/
Pubrica Academy, ‘PRISMA 2020: Scope, Components and Common Misinterpretations of the Reporting Guideline’ (Pubrica, 9 October 2026) <https://pubrica.com/academy/concepts-definitions/preferred-reporting-items-for-systematic-reviews-and-meta-analyses/> accessed 15 October 2026.
Pubrica Academy. PRISMA 2020: Scope, Components and Common Misinterpretations of the Reporting Guideline. [Internet]. Pubrica; 2026 Oct 9 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/concepts-definitions/preferred-reporting-items-for-systematic-reviews-and-meta-analyses/
Pubrica Academy, “PRISMA 2020: Scope, Components and Common Misinterpretations of the Reporting Guideline,” Pubrica, Oct. 9, 2026. [Online]. Available: https://pubrica.com/academy/concepts-definitions/preferred-reporting-items-for-systematic-reviews-and-meta-analyses/
@misc{preferred_reporting_items_for_systemat_2026,
author = {{Pubrica Academy}},
title = {PRISMA 2020: Scope, Components and Common Misinterpretations of the Reporting Guideline},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/concepts-definitions/preferred-reporting-items-for-systematic-reviews-and-meta-analyses/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Methods wording and checklist-handling stub
Paste this into your methods section and complete the blanks. It separates the reporting claim from the conduct claim, which is the distinction most published reviews collapse.
PRISMA METHODS WORDING
REPORTING CLAIM (what PRISMA covers)
"This review is reported in accordance with the PRISMA 2020 statement.
The completed PRISMA 2020 checklist, indicating the section in which
each item is addressed, is provided as Supplementary File ___."
Extension applied, if any: ______________________
e.g. "The search is reported following PRISMA-S."
"Reported following PRISMA-DTA for diagnostic accuracy reviews."
"Reported following PRISMA-ScR for scoping reviews."
CONDUCT CLAIM (what PRISMA does NOT cover — cite your real source)
Methodological source followed: ______________________
e.g. "The review was conducted following the methods set out in the
Cochrane Handbook for Systematic Reviews of Interventions."
Protocol registered? [ ] yes, registry and number: ______________
[ ] no — state why: ______________
Protocol prepared using PRISMA-P? [ ] yes [ ] no
CONDUCT DETAIL THE CHECKLIST ASKS YOU TO REPORT
Databases and platforms searched, with dates: ______________
Date of last search: ______________
Number of screeners at title/abstract: ____ independent? [ ]
Number of screeners at full text: ____ independent? [ ]
Disagreement resolution procedure: ______________________
Risk-of-bias tool used, and by how many assessors: ______________
Synthesis model, with the REASON for choosing it: ______________
Heterogeneity assessment reported: ______________
Certainty-of-evidence approach, if used: ______________
FLOW DIAGRAM RECONCILIATION (check the arithmetic before submission)
Records identified by database search ............ ______
Records from other sources ....................... ______
Duplicates removed ............................... ______
Records screened ................................. ______
Records excluded at title/abstract ............... ______
Full texts assessed .............................. ______
Full texts excluded, WITH REASONS listed ......... ______
Studies included in the review ................... ______
Studies included in the synthesis ................ ______
[ ] Every stage adds up
[ ] Reasons are given for every full-text exclusion
[ ] Reviews-in-synthesis differs from reviews-included only where
explained in the text
SENTENCES TO DELETE IF PRESENT
[ ] "conducted in accordance with PRISMA"
[ ] "PRISMA-compliant review"
[ ] "a comprehensive search was performed" with no strategy given
[ ] "relevant studies were selected" with no screener count Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica maps draft manuscripts against the PRISMA 2020 items and the extension that matches the review type, returns the completed checklist with section-level locations rather than a column of ticks, and reconciles the flow diagram arithmetic before peer review. Where the checklist reveals a conduct gap rather than a reporting gap, Pubrica identifies which it is, because the two require different remedies.